Quick Answer: Retatrutide is a triple agonist drug in development by Eli Lilly that activates GIP, GLP-1, and glucagon receptors simultaneously. In Phase 2 trials published in the New England Journal of Medicine (2023), the highest dose produced approximately 24% mean body weight loss over 48 weeks — greater than any previously published GLP-1 class drug. Phase 3 trials are ongoing as of 2025; retatrutide has not been approved by the FDA and is not currently available for prescription.
The GLP-1 drug landscape has evolved faster than almost any other pharmaceutical category in recent history. In 2021, semaglutide produced weight loss numbers that researchers called unprecedented. In 2023, tirzepatide improved on those numbers. And now, a third compound — retatrutide — has produced Phase 2 data that raises the ceiling further.
Understanding what the trials actually showed, what the dosing protocol involved, and what is still unknown is essential context for anyone researching this drug class. This article focuses on the evidence: what was measured, how, and what conclusions can and cannot be drawn.
What Is Retatrutide?
Retatrutide (development code LY3437943) is an investigational drug developed by Eli Lilly and Company. Like semaglutide and tirzepatide, it is administered as a once-weekly subcutaneous injection. Unlike its predecessors, retatrutide activates not two but three metabolic receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors.
This triple-receptor mechanism is why the drug is referred to as a "triple agonist" — it works simultaneously on three distinct but related hormonal pathways involved in energy homeostasis, blood glucose regulation, and fat metabolism. No currently approved drug activates all three.
As of early 2025, retatrutide is in Phase 3 clinical trials. It has not received FDA approval and is not available for prescription through licensed medical channels.
The Triple Agonist Mechanism: GIP + GLP-1 + Glucagon
To understand why the Phase 2 weight loss data is larger than for semaglutide or tirzepatide, it helps to understand what each receptor contributes.
GLP-1 (glucagon-like peptide-1): The most well-characterized of the three. GLP-1 receptor activation suppresses appetite via the hypothalamus, slows gastric emptying, stimulates glucose-dependent insulin secretion, and reduces glucagon output. Semaglutide is a selective GLP-1 receptor agonist. Virtually all weight loss from semaglutide occurs through this pathway.
GIP (glucose-dependent insulinotropic polypeptide): GIP was historically considered to play only a minor role in weight management — primarily as an incretin hormone supporting insulin secretion. Tirzepatide's clinical success upended that assumption. Dual GIP/GLP-1 agonism appears to be additive for weight loss through complementary and partially distinct mechanisms, including possible direct effects on adipose tissue and synergistic action at the hypothalamic level. The Jastreboff et al. SURMOUNT-1 trial (New England Journal of Medicine, 2022) demonstrated that tirzepatide produced approximately 21% mean weight loss — substantially more than semaglutide's ~15% from GLP-1 alone.
Glucagon: The addition of glucagon receptor agonism in retatrutide is the key mechanistic distinction from tirzepatide. Glucagon is typically associated with raising blood glucose (its role in the liver is to stimulate glycogenolysis and gluconeogenesis), which would ordinarily make it a counterintuitive target in a metabolic drug. However, glucagon receptor activation in the context of co-administered GLP-1 agonism (which counters the hyperglycemic effect) adds another dimension: increased energy expenditure, enhanced fat oxidation, and additional appetite suppression via hypothalamic pathways. The glucagon component essentially adds a thermogenic and lipolytic element to the appetite-suppression profile of GLP-1.
This three-pathway mechanism — appetite suppression, insulin regulation, and increased fat oxidation — is the theoretical basis for why retatrutide's weight loss data exceeds tirzepatide's.
What Phase 2 Trials Actually Showed
The primary Phase 2 data for retatrutide was published in a randomized, double-blind, placebo-controlled trial: Jastreboff et al. (2023, New England Journal of Medicine). The trial enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, without type 2 diabetes. The treatment period was 48 weeks.
Participants were randomized across multiple dose arms — 1 mg, 4 mg, 8 mg, and 12 mg weekly — alongside a placebo group. The primary endpoint was percentage change in body weight from baseline.
Key findings:
- The 12 mg dose arm produced a mean weight loss of approximately 24.2% of body weight at 48 weeks.
- The 8 mg dose arm produced approximately 22.8% mean weight loss.
- The 4 mg dose arm produced approximately 17.3% mean weight loss.
- The 1 mg dose arm produced approximately 8.7% mean weight loss.
- Placebo: approximately 2.1% weight change.
These numbers are notable not just in absolute terms but in context. No GLP-1 class drug had previously shown 24% mean weight loss in a Phase 2 population in a 48-week window. The trial also showed dose-dependent improvements in waist circumference, blood pressure, and fasting lipid profiles.
One important caveat: this was a Phase 2 trial. It was designed primarily to establish dose-response relationships and safety signals, not to confirm efficacy at scale. Phase 3 trials, which are substantially larger and longer in duration, are required to confirm these results before FDA review.
Phase 3 Status
As of 2025, Eli Lilly is conducting Phase 3 trials for retatrutide under the TRIUMPH program, including trials in adults with obesity (without diabetes), adults with type 2 diabetes, and adults with obesity-related cardiovascular disease. These trials are expected to be the largest-scale evaluation of the drug and will generate the long-term safety and efficacy data required for a New Drug Application (NDA) to the FDA.
No Phase 3 results have been published as of early 2025. The drug remains investigational.
Retatrutide Dosing: The Protocol Used in Trials
One of the most-searched aspects of retatrutide is the dosing protocol — reflecting the interest of people who are actively researching whether or how this drug might be used. It is worth being precise about what was actually studied.
In the Phase 2 trial, the dosing protocol followed a dose-escalation schedule designed to minimize gastrointestinal side effects. Participants did not start at their target dose; they were escalated gradually over multiple weeks. The general progression for the highest-dose cohort moved through:
- 1 mg/week — initial dose, weeks 1–4
- 2 mg/week — escalation step
- 4 mg/week — middle step
- 8 mg/week — higher step
- 12 mg/week — maximum maintenance dose (reached at approximately week 24 for highest-dose participants)
This slow titration is consistent with the approach used in tirzepatide and semaglutide dosing protocols — it gives the gut time to adapt to GLP-1 pathway activation and reduces the severity of nausea and vomiting that tend to occur when doses are escalated too rapidly.
The weekly subcutaneous injection format is the same delivery mechanism used by semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) — a small needle injected into subcutaneous fat, typically in the abdomen, thigh, or upper arm.
Critical note: These dosing protocols were conducted under close clinical supervision, with regular laboratory monitoring, dose adjustments based on individual tolerability, and careful screening of participants for contraindications. The Phase 2 protocol is not a dosing guide for self-administration.
What's Not Yet Known
The Phase 2 data is promising, but substantial unknowns remain — and these matter considerably for understanding the drug's eventual clinical profile.
Long-term safety data is incomplete. The Phase 2 trial ran 48 weeks. Phase 3 trials will extend the observation window substantially, but long-term cardiovascular outcomes, renal effects, and cancer-related data will not be fully characterized until post-approval surveillance — if and when approval occurs.
Thyroid C-cell effects. All GLP-1 receptor agonists currently carry an FDA black box warning based on findings of thyroid C-cell tumors in rodent studies at high doses. Whether this risk applies to retatrutide — and particularly whether the glucagon receptor component modifies this profile — is not yet established in humans.
Weight regain on discontinuation. Semaglutide trials documented substantial weight regain when the drug was stopped. Whether retatrutide produces a similar rebound effect, and at what rate, has not been established.
Muscle mass and body composition. At 24% body weight loss, the question of lean mass preservation becomes pressing. Rapid weight loss at this magnitude can result in significant muscle loss if not deliberately countered with resistance training and protein intake. Phase 2 did not comprehensively characterize body composition changes.
FDA timeline. No approval date has been announced. Phase 3 completion, NDA submission, and FDA review typically take several years from Phase 2 publication. Based on the drug development timeline, retatrutide is unlikely to be available for prescription before 2026 at the earliest — and that estimate is optimistic.
Why People Are Searching for It Before It's Available
The search volume for retatrutide has grown substantially since the Phase 2 publication. This reflects a pattern that has become common in the GLP-1 drug category: people with significant weight loss goals are following the clinical pipeline actively, researching drugs before they are approved or available.
This interest has also created a market for compounding pharmacy versions of retatrutide — unregulated preparations that have not been clinically validated, may be improperly dosed, and carry risks of unknown purity and contamination. Unlike compounded semaglutide (which at least uses the same active molecule as an FDA-approved drug), compounded retatrutide is a novel compound with no approved reference product and no established safety profile for unsupervised use. The FDA has issued guidance cautioning against unapproved compounded versions of investigational drugs.
The Natural GLP-1 Pathway: What Works Now
While pharmaceutical development of triple agonists continues, the GLP-1 pathway itself — the biological system these drugs leverage — can be supported through non-pharmacological means. These approaches don't replicate what retatrutide or any GLP-1 drug does at the receptor level. They work upstream: supporting your body's own GLP-1 production through gut bacteria, dietary fiber, and specific nutrient-sensing mechanisms.
The research supporting natural GLP-1 pathway support includes:
- Short-chain fatty acid production via gut bacteria: Fermentable dietary fiber is metabolized by Bifidobacterium, Akkermansia, and SCFA-producing bacteria into butyrate and propionate, which bind FFAR2/FFAR3 receptors on intestinal L-cells and stimulate GLP-1 secretion (Tolhurst et al., 2012, Diabetes).
- Akkermansia muciniphila and the P9 pathway: Akkermansia produces a surface protein (P9) that directly stimulates GLP-1 secretion via ICAM-2 receptor signaling. Depommier et al. (Nature Medicine, 2019) documented metabolic improvements from Akkermansia supplementation in overweight adults through this mechanism.
- Berberine: A plant alkaloid that activates AMPK, modulates gut microbiome composition toward SCFA producers, and has demonstrated blood glucose and HbA1c improvements in multiple small human trials.
These mechanisms produce real effects — improved post-meal satiety, modest metabolic improvements, better glucose regulation — within the bounds of physiological GLP-1 production. They are not pharmaceutical alternatives. They are upstream biological support systems that work through the same hormonal architecture these drugs are built around.
Who This Is For
People researching the GLP-1 drug class who want an accurate, evidence-grounded understanding of what retatrutide is, how it compares to approved drugs, and where it sits in the development pipeline.
People not yet medically eligible for or choosing not to use pharmaceutical GLP-1 interventions who want to support their metabolic health through documented biological mechanisms available now.
People on GLP-1 pathway drugs who want to understand the upstream biological system — gut microbiome health, GLP-1 production capacity, SCFA-producing bacteria — that pharmaceutical drugs are built on top of.
The Natural Upstream Alternative
Plus+Ultra GLPLUS+ 10-in-1 — A multi-pathway GLP-1 support formula designed to support your body's own GLP-1 production through gut bacteria optimization, SCFA pathway activation, and key ingredients including Akkermansia muciniphila, berberine, and prebiotic fiber. It works upstream of the receptor — supporting the biological production system, not bypassing it. Visit the product page to learn more about what's in it and how the mechanisms work.
